New agreement signed with i2020 to tackle neurological diseases
We are delighted to announce that that we have another agreement signed with i2020 accelerator, following on from the one in 2019. This supports our group’s efforts to identify and develop strategies for neurological diseases with no or inadequate treatments by targeting NOS1AP.
Last updated on March 5, 2025
Recent Posts
- The Novo Nordisk Foundation has awarded funding of approximately one million euros to a research project led by Professor Jukka WestermarckThe Novo Nordisk Foundation has awarded funding of approximately one million euros to a research Read moreAugust 21, 2026
- Call is now open for BioCity Turku research programs 2027-2031Life science researchers on the Turku campus are invited to submit proposals for new BioCity Read moreJune 10, 2026
- Early-career researchers invited to BioCity Pre-Symposium on 26 August. Registration is now open!Doctoral researchers at BioCity Turku are organising a pre-symposium on 26 August 2026, offering early-career Read moreApril 30, 2026
- 35th BioCity Symposium is arranged 27–28 August 2026. Registration is now open!This year, BioCity Symposium is arranged on-site in Mauno Koivisto Centre, BioCity in 27–28 August Read moreApril 14, 2026
- Turku Protein Core Opens Two New PositionsTurku Protein Core (TuProtCore) is seeking to fill two roles: a Project Specialist in Service Read moreApril 7, 2026
- The Jane and Aatos Erkko Foundation has granted nearly €1 million to support research led by Professor Jukka Westermarck993 000 € was granted to a research project led by our Group Leader Professor Jukka Read moreApril 2, 2026